Breast Cancer

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors.

APOBEC3 mutagenesis emerges as a key factor in breast cancer treatment resistance, offering new avenues for targeted therapies and predictive biomarkers.

In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration.

Combining olaparib with neoadjuvant chemotherapy enhances survival rates for early-stage gBRCAm triple-negative breast cancer, offering new hope for patients.

Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies.

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

Pharmacists can educate patients on nonpharmacologic strategies that help improve survival outcomes.

Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Study shows a significant decline in breast cancer mortality across multiple subtypes.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Breast cancer treatment is highly individualized and based on the stage, hormone receptor status, HER2 expression, and patient-specific factors.

Pharmacists share key insights about the use of ADCs for treatment of breast cancer.

Panelists discuss how there have been many new agents being studied and released at the current time and how the development of these agents is moving at a rapid pace. The adverse effect profiles of newer antibody-drug conjugates create a greater opportunity for pharmacists to be involved in toxicity management.

Fatty acid metabolism plays a critical role in treatment responses.

Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.

Evolving breast cancer risk models and prevention methods are necessary to improve patient outcomes, according to Sagar Sardesai, MD.

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.